Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced that it has received regulatory and IRB approvals in Taiwan to open the next stage (Part 2) ...
Yahoo Finance

EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients

The U.S. Food and Drug Administration (FDA) on Monday cleared the amendment to Lantern Pharma Inc.’s (NASDAQ:LTRN) Investigational New Drug (IND) application for the Phase 1b/2 trial of LP-184 in a ...

Biomednewsbreaks - Lantern Pharma (NASDAQ: LTRN) Receives Taiwan Approvals To Advance Phase 2 HARMONIC(TM) Trial

Receives Taiwan Approvals To Advance Phase 2 HARMONIC(TM) Trial. Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, received regulatory and Institutional Review Boa ...
MarketScreener

Lantern Pharma Inc. Receives Taiwan Approvals to Open Next Stage of Phase 2 Harmonic Trial of Lp-300 in Never-Smoker, Egfr-Mutant Nsclc

Lantern Pharma Inc. announced that it has received regulatory and IRB approvals in Taiwan to open the next stage (Part 2) of its Phase 2 HARMONIC? trial of LP-300. The Taiwan Food and Drug ...